Certain chemical entities, compositions, and methods

US9340570B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9340570-B2
Application numberUS-201313873059-A
CountryUS
Kind codeB2
Filing dateApr 29, 2013
Priority dateApr 29, 2012
Publication dateMay 17, 2016
Grant dateMay 17, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

First claim

Opening claim text (preview).

What is claimed is: 1. A Compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 11 and R 12 are independently chosen from hydrogen, hydroxy, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted heterocycloalkyloxy, optionally substituted aminocarbonyloxy, optionally substituted acyloxy, optionally substituted alkoxycarbonyloxy, and optionally substituted amino; or R 1 and R 2 , or R 5 and R 6 , or R 7 and R 8 , or R 9 and R 10 , or R 11 and R 12 mutually independently, together in each case denote an oxo group (═O); or R 4 and R 5 may optionally be joined together with any intervening atoms to form an optionally substituted heterocycloalkyl ring; R 7 is chosen from hydrogen, hydroxy, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted heterocycloalkyloxy, optionally substituted aminocarbonyloxy, optionally substituted acyloxy, optionally substituted alkoxycarbonyloxy, and optionally substituted amino; R 8 is chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 13 is chosen from hydrogen, optionally substituted alkyl, and formyl; R 14 is chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; R 15 is —CONR 17 R 18 , where R 17 and R 18 are joined together with any intervening atoms to form an optionally substituted heterocycloalkyl ring; W 1 is chosen from the following moieties: wherein Y is chosen from O and NR 21 ; R 20 is chosen from cyano, halo, hydroxy, azido, nitro, carboxy, sulfinyl, sulfanyl, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted heterocycloalkyloxy, optionally substituted alkoxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryloxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted amino, optionally substituted acyl, optionally substituted alkoxycarbonyl, optionally substituted aminocarbonyl, optionally substituted aminosulfonyl, optionally substituted carbaminodoyl, and optionally substituted alkynyl; R 21 is chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; W 2 is chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, and optionally substituted alkynyl; and m is selected from 0, 1, 2, and 3. 2. The compound of claim 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 11 and R 12 are independently chosen from hydrogen, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aminocarbonyloxy, optionally substituted acyloxy, optionally substituted alkoxycarbonyloxy, and optionally substituted amino. 3. The compound of claim 2 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 11 and R 12 are independently chosen from hydrogen, hydroxy, and optionally substituted alkyl. 4. The compound of claim 3 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 11 and R 12 are independently chosen from hydrogen, hydroxy, and methyl. 5. The compound of claim 4 wherein R 4 is hydroxy. 6. The compound of claim 1 wherein R 4 and R 5 are joined together with any intervening atoms to form an optionally substituted 3- to 8-membered heterocycloalkyl ring. 7. The compound of claim 6 wherein R 4 and R 5 are joined together with any intervening atoms to form an oxirane ring. 8. The compound of claim 1 wherein R 7 is chosen from hydrogen, hydroxy, optionally substituted alkoxy, optionally substituted aminocarbonyloxy, optionally substituted acyloxy, optionally substituted alkoxycarbonyloxy, and optionally substituted amino. 9. The compound of claim 8 wherein R 7 is chosen from hydrogen and optionally substituted acyloxy. 10. The compound of claim 9 wherein R 7 is chosen from hydrogen and —OCOCH 3 . 11. The compound of claim 1 wherein R 8 and W 2 are independently chosen from hydrogen and optionally substituted alkyl. 12. The compound of claim 1 wherein R 13 is chosen from hydrogen and optionally substituted alkyl. 13. The compound of claim 12 wherein R 13 is chosen from hydrogen, methyl, and hydroxymethyl. 14. The compound of claim 1 wherein Y is chosen from O, NH and NCH 3 . 15. The compound of claim 14 wherein Y is O. 16. The compound of claim 1 wherein R 20 is chosen from cyano, halo, hydroxy, carboxy, sufonyl, optionally substituted alkoxy, optionally substituted alkoxycarbonyl, optionally substituted alkyl, optionally substituted amino, optionally substituted acyl, optionally substituted alkoxycarbonyl, optionally substituted aminocarbonyl, and optionally substituted aminosulfonyl. 17. The compound of claim 1 wherein m is 0. 18. The compound of claim 1 wherein the compound of Formula I is chosen from compounds of Formula Ia 19. The compound of claim 1 wherein the compound of Formula I is chosen from compounds of Formula Ib 20. The compound of claim 1 wherein the compound of Formula I is chosen from compounds of Formula Ic 21. The compound of claim 1 wherein the compound of Formula I is chosen from compounds of Formula Ie 22. The compound of claim 1 wherein the compound of Formula I is chosen from compounds of Formula If 23. The compound of claim 1 wherein the compound of Formula I is chosen from compounds of Formula Ig 24. The compound of claim 1 wherein the compound of Formula I is chosen from compounds of Formula Ih 25. The compound of claim 1 wherein the compound of Formula I is chosen from compounds of Formula Ii 26. The compound of claim 1 wherein the compound of Formula I is chosen from compounds of Formula Ij

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton · CPC title

  • at position 14(15) · CPC title

  • not condensed · CPC title

  • Unsubstituted amino radicals · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9340570B2 cover?
Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
Who is the assignee on this patent?
Qian Xiangping, Neupharma Inc
What technology area does this patent fall under?
Primary CPC classification C07J41/0011. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).